Verine J L, Coic H, Bertrand G, Lépinard V, Soret J Y
Ann Urol (Paris). 1986;20(3):175-85.
Bladder lavage fluid was examined using flow-cytometry (FCM) in 112 patients with transitional cell carcinoma seen over 30 months. FCM investigates the entire mucosa, furnishes indications as to the possible existence of dysplasia or carcinoma in situ, and thus provides for a more accurate evaluation of the evolutive potential of the "bladder disease". FCM consists in the automated assay of the DNA content of epithelial cells. The test is positive when "tumorous" diploid or aneuploid cells are demonstrated. The diagnostic sensitivity of FCM is comparable to that of cytologic diagnosis on bladder lavage specimens, but FCM has the additional advantage of detecting those patients at high risk for disease progression by measurement of the DNA index. Grade 1 and 2 tumors are diploid in 70% of patients, against only 14% for grade 3 tumors and carcinomas in situ. Follow up of 25 grade 2 patients and determination of the recurrence index clearly establishes the prognostic significance of the degree of tumorous ploidy. Furthermore, the effectiveness of endovesical chemotherapy can be monitored using FCM measurement of the aneuploidy index.
在30个月内对112例移行细胞癌患者的膀胱灌洗液进行了流式细胞术(FCM)检查。FCM可对整个黏膜进行检测,提示发育异常或原位癌的可能存在,从而更准确地评估“膀胱疾病”的发展潜力。FCM包括对上皮细胞DNA含量的自动检测。当检测到“肿瘤性”二倍体或非整倍体细胞时,检测结果为阳性。FCM的诊断敏感性与膀胱灌洗标本的细胞学诊断相当,但FCM还有一个额外优势,即通过测量DNA指数来检测疾病进展风险高的患者。1级和2级肿瘤患者中70%为二倍体,而3级肿瘤和原位癌患者中只有14%为二倍体。对25例2级患者进行随访并确定复发指数,明确证实了肿瘤倍体程度的预后意义。此外,可通过FCM测量非整倍体指数来监测膀胱内化疗的效果。